Vertex Pharmaceuticals
VRTX
$0.08 (0.02%)
1D
1W
3M
1Y
5Y
ALL
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Investors Business Daily • 2 hours ago • VRTX
Analysts Say 12 Stocks Will Profit Most From Trump's ReignThe Motley Fool • 3 days ago • VRTX
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens NextThe Motley Fool • 6 days ago • VRTX
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the BounceThe Motley Fool • 9 days ago • VRTX
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for DecadesCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.